Clinical research has shown that the combination of PD-1/PD-L1 inhibitors and CTLA-4 inhibitors resulted in enhanced effector T-cell action and attenuated suppressor T-cell action, resulting in stronger anti-tumor effects than single-agent ICIs (Figure 2B) (53). This evidence concerns the gene PDCD1 and neoplasm.